U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07424560) titled 'Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer' on Feb. 14.
Brief Summary: Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response. However, existing mutation detection approaches are often limited by high cost, complex workflows, or insufficient capacity for multiplex and low-frequency mutation analysis, which restricts their routine clinical application.
The purpose of this study is to establish and clinically validate a multiplex mutation detection system for bladder canc...